Medroxyprogesterone acetate has minimal impact on HIV-1 replication in ectocervical tissue ex vivoMariko, Hawa (2017) Medroxyprogesterone acetate has minimal impact on HIV-1 replication in ectocervical tissue ex vivo. Master's Thesis, University of Pittsburgh. (Unpublished)
AbstractA link between use of the contraceptive depomedroxyprogesterone acetate (DMPA) and risk of HIV-1 acquisition has been demonstrated in epidemiologic studies. Peak medroxyprogesterone-17-acetate (MPA) levels occur 4 days post-injection with serum progestin levels of 2 nM. However, other studies have evaluated its in vitro effects at supraphysiologic concentrations resulting in immune modulation of epithelial cell lines and peripheral blood mononuclear cells. To formally evaluate MPA effects on HIV-1 infection in a more physiologic model, we utilized our polarized ectocervical tissue explant model. Our hypothesis is physiologic concentrations of MPA will not affect HIV-1 replication in ectocervical tissue ex vivo. Human ectocervical tissue was processed into polarized explants. Explants were cultured alone (control) or with MPA in the basolateral compartment at physiological (0.05nM, 0.5nM, 1nM, 5nM) (n=17) or higher concentrations (500nM, 5μM, 500μM) (n=10) for 48 h, infected Viral replication over 21 days in the presence of supraphysiologic concentrations of MPA indicated suppression, while that in the presence of physiologic concentrations was not significantly different from the control. Evaluation of cytokine markers indicated a hormone dose-dependent relationship between decreasing MPA concentrations (500μM-5nM) and increasing expression of pro-inflammatory cytokines approaching levels of the control, which were significant for IL-12 (p40), IL-6, and IL-8. MPA does not significantly affect HIV-1 replication at physiologic concentrations but has an overall suppressive effect on replication at supraphysiologic concentrations in ectocervical tissue in cervical tissue ex vivo. The public health significance of DMPA continuation requires balancing unintended pregnancy while diminishing HIV-1 acquisition risk, especially when the risks of infection do not outweigh the contraceptive benefits. Share
Details
MetricsMonthly Views for the past 3 yearsPlum AnalyticsActions (login required)
|